Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”…
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC Professional…
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…
Lucid Diligence Brief: Turbine $25m Series B for virtual biology
Lucid Diligence Brief: Turbine $25m Series B for virtual biology Professional…
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology
Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology…
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in localized prostate cancer
Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in…
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…
Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide licensing agreement
Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide…
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…